Levine J F
New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.
Med Clin North Am. 1987 Nov;71(6):1135-45. doi: 10.1016/s0025-7125(16)30801-x.
This article reviewed the past experience and updated the present data on vancomycin. In recent years, with the release of more purified preparations of vancomycin and new clinical problems facing the clinician (that is, increasing prevalence of serious methicillin-resistant staphylococcal infections; use of hemodialysis and CAPD; widespread use of prosthetic devices; aggressive chemotherapy), the indication for vancomycin use has increased dramatically. More information is needed on the distribution of vancomycin in body tissues and the incidence and mechanisms of toxicity. Close surveillance of in vitro susceptibility patterns will be necessary as widespread use of vancomycin continues to increase.
本文回顾了过去使用万古霉素的经验并更新了当前数据。近年来，随着更纯的万古霉素制剂的推出以及临床医生面临的新的临床问题（即严重耐甲氧西林葡萄球菌感染的患病率增加；血液透析和持续性非卧床腹膜透析的使用；人工装置的广泛使用；积极的化疗），万古霉素的使用指征急剧增加。关于万古霉素在人体组织中的分布以及毒性的发生率和机制，还需要更多信息。随着万古霉素的广泛使用持续增加，密切监测体外药敏模式将很有必要。
